August 29th 2025
Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.
Monitoring adolescents with cystic fibrosis
July 1st 2006abstract: There is increasing evidence that close monitoring and early intervention lead to better outcomes in patients with cystic fibrosis. At each office visit, spirometry should be performed and sputum culture specimens should be obtained; if the patient cannot produce sputum, a throat culture can be done instead. New respiratory symptoms or other evidence of worsening lung disease should prompt antibiotic therapy, increased airway clearance, and adjunctive anti-inflammatory medication as appropriate. Close attention should be paid to the patient's diet, appetite, stooling pattern, and growth measurements. Adolescents should be given additional information about their medications and adjunctive therapies to encourage them to take on a larger role in their own care. (J Respir Dis.2006;27(7):298-305)
Woman With Nausea, Emesis, and Abdominal Pain After Splenic Artery Embolization
July 1st 2006A 68-year-old woman presents with recurrent nausea, vomiting, left upper quadrant pain, decreased appetite, and a 2.3-kg (5-lb) weight loss 1 month after she underwent selective splenic artery embolization for refractory thrombocytopenia secondary to hypersplenism.
FDA Approves First Drug for Parkinson's Dementia
June 28th 2006ROCKVILLE, Md. - The FDA has given Exelon (rivastigmine), already approved for treatment of mild-to-moderate Alzheimer's dementia, the added indication of mild-to-moderate Parkinson's dementia. It is the first agent approved for the Parkinson's condition.
ADA: Investigational Drug Produces Significant Weight Loss for Obese
June 13th 2006WASHINGTON - Lorcaserin, an investigational drug for the treatment of obesity, was successful at producing weight loss ranging between four and 7.9 pounds (1.8 to 3.6 kg) in a 12-week study, reported investigators here.
ADA: Investigational Type 2 Diabetes Drug Lowers Weight and Improves Insulin Function
June 13th 2006WASHINGTON - Liraglutide, an investigational injectable drug for type 2 diabetes, has produced significant decreases in HbA1c levels, as well as significant and sustained weight loss, according to phase 2 studies.
Coffee Consumption May Protect Liver from Alcohol
June 12th 2006OAKLAND, Calif. ? Coffee may help protect the livers of heavy alcohol drinkers. In a cohort study of Kaiser Permanente members, drinking one to three cups of coffee a day was associated with a 40% decrease in the risk of alcoholic cirrhosis versus drinking less than one cup.
FDA Approves First Drug for Treatment of Seasonal Affective Disorder
June 12th 2006ROCKVILLE, Md. - The FDA today approved Wellbutrin XL (bupropion extended release) for prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD). It is the first drug approved for SAD.
ADA: Investigational Januvia Put Through Its Paces for Diabetes
June 11th 2006WASHINGTON ? Januvia (sitagliptin), an investigational oral agent for type 2 diabetes, appears to be effective when given as a monotherapy or as an adjunct to Glucophage (metformin) or Actos (pioglitazone), reported researchers here.
Woman With Fever, Malaise, and Lesions on Her Hands and Feet
June 1st 2006A 22-year-old woman presents with fever and malaise of1 month’s duration. About 3 weeks earlier she went to theemergency department. Erythromycin was prescribed,and the patient was told to seek medical attention if hercondition did not improve. Since that time, her healthhas worsened, the fever has continued, and she has lostweight. She says she has had painful areas on her handsand feet but no rash.
Bipolar Disorder: How to Recognize and Treat in Primary Care
June 1st 2006Patients with psychiatric disordersoften present a diagnostic challenge-even for psychiatrists. Their demeanormay not readily reveal the nature orseverity of the problem. Nevertheless,there are clues that can help you sortthrough the differential and arrive atthe correct diagnosis.
Polycystic Ovary Syndrome: When to Suspect
June 1st 2006ABSTRACT: The key features of polycystic ovary syndrome (PCOS) are menstrual bleeding disturbances caused by chronic oligoovulation or anovulation and clinical or biochemical hyperandrogenism. The finding of polycystic ovaries on ultrasonography alone has limited predictive value. Obesity often coexists with PCOS and can exacerbate metabolic disturbances, particularly insulin resistance, but it is not a diagnostic finding. Laboratory results can rule out other conditions in the differential, such as an androgen- producing neoplasm, hypothyroidism, and late-onset congenital adrenal hyperplasia.